These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 3106101)

  • 1. Ovarian stimulation by a combination of a gonadotropin-releasing hormone agonist and gonadotropins for in vitro fertilization.
    Neveu S; Hedon B; Bringer J; Chinchole JM; Arnal F; Humeau C; Cristol P; Viala JL
    Fertil Steril; 1987 Apr; 47(4):639-43. PubMed ID: 3106101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled ovarian hyperstimulation for in vitro fertilization using buserelin and gonadotropin in patients with previous failed cycles.
    Loong EP; Tam PP; Chiu TT; Chan MY; Panesar NS; Lau J
    Asia Oceania J Obstet Gynaecol; 1990 Dec; 16(4):297-300. PubMed ID: 2129187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of serum follicle stimulating hormone to luteinizing hormone ratio during buserelin acetate-induced pituitary desensitization on ovarian response to exogenous gonadotrophins in an in-vitro fertilization and embryo transfer programme.
    Yamashita T; Ishimaru T; Fujishita A; Kawano M; Yamabe T
    Hum Reprod; 1996 Aug; 11(8):1615-9. PubMed ID: 8921103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist.
    Itskovitz J; Boldes R; Levron J; Erlik Y; Kahana L; Brandes JM
    Fertil Steril; 1991 Aug; 56(2):213-20. PubMed ID: 1906406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful induction of ovulation and conception with combined gonadotropin-releasing hormone agonist plus highly purified follicle-stimulating hormone in patients with polycystic ovarian disease.
    Lanzone A; Fulghesu AM; Spina MA; Apa R; Menini E; Caruso A; Mancuso S
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1253-8. PubMed ID: 3119655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of gonadotrophin-releasing hormone agonist on follicular development in patients with polycystic ovary syndrome in an in-vitro fertilization and embryo transfer programme.
    Gersak K; Meden-Vrtovec H; Tomazevic T
    Hum Reprod; 1994 Sep; 9(9):1596-9. PubMed ID: 7836506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple follicular development and ovarian steroidogenesis following subcutaneous administration of a highly purified urinary FSH preparation in pituitary desensitized women undergoing IVF: a multicentre European phase III study.
    Howles CM; Loumaye E; Giroud D; Luyet G
    Hum Reprod; 1994 Mar; 9(3):424-30. PubMed ID: 8006130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of different ovarian stimulation protocols for in vitro fertilization.
    Pados G; Tarlatzis BC; Bontis J; Lagos S; Papadimas J; Spanos E; Mantalenakis S
    Gynecol Endocrinol; 1995 Jun; 9(2):103-12. PubMed ID: 7502685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A controlled study of luteinizing hormone-releasing hormone agonist (buserelin) for the induction of folliculogenesis before in vitro fertilization.
    MacLachlan V; Besanko M; O'Shea F; Wade H; Wood C; Trounson A; Healy DL
    N Engl J Med; 1989 May; 320(19):1233-7. PubMed ID: 2496310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pregnancy following induction of ovulation with pure FSH after suppression of endogenous gonadotropins with subcutaneous buserelin.
    Albert PJ; Schläfke J; Kaesemann H; Gille J
    Arch Gynecol Obstet; 1987; 241(1):53-6. PubMed ID: 3118825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro fertilization for women with pure tubal occlusion: the impact of short gonadotropin-releasing hormone agonist treatment.
    Luxman D; Cohen JR; Lessing JB; Yovel I; David MP; Ami A
    Fertil Steril; 1995 Feb; 63(2):357-60. PubMed ID: 7843443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group.
    Borm G; Mannaerts B
    Hum Reprod; 2000 Jul; 15(7):1490-8. PubMed ID: 10875855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
    Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
    Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized comparative study of purified follicle stimulating hormone and human menopausal gonadotropin after pituitary desensitization with Buserelin for superovulation and in vitro fertilization.
    Bentick B; Shaw RW; Iffland CA; Burford G; Bernard A
    Fertil Steril; 1988 Jul; 50(1):79-84. PubMed ID: 3133251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A preliminary study on reduced dose (33 or 25 microg) gonadotropin-releasing hormone agonist long protocol for multifollicular ovarian stimulation in patients with high basal serum follicle-stimulating hormone levels undergoing in vitro fertilization-embryo transfer.
    Ku SY; Choi YS; Jee BC; Suh CS; Choi YM; Kim JG; Moon SY; Kim SH
    Gynecol Endocrinol; 2005 Oct; 21(4):227-31. PubMed ID: 16316845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Stimulation of ovarian function with gonadotropins following suppression of endogenous gonadotropin secretion by long-term infusion of the LHRH analog buserelin].
    Geisthövel F; Bliefert R; Geyer H; Breckwoldt M; Sandow J
    Geburtshilfe Frauenheilkd; 1987 Apr; 47(4):240-5. PubMed ID: 3109997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pituitary and ovarian suppression rate after high dosage of gonadotropin-releasing hormone agonist.
    Bider D; Ben-Rafael Z; Shalev J; Goldenberg M; Mashiach S; Blankstein J
    Fertil Steril; 1989 Apr; 51(4):578-81. PubMed ID: 2494078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.